May 2015, Vol 8, No 3

Editorial

Did the “HEN” Lay a Rotten Egg?

David B. Nash, MD, MBA

Regulatory

Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis

J.D. Kleinke, Nancy McGee, DrPH

Stakeholder Perspective

Financing Drug Innovation: Cost versus Cure

by Joseph R. Antos, PhD

Business

Demonstrating Value for Biosimilars: A Conceptual Framework

Sally Amanuel, MSc, MA, MBA, Paola Antonini, MD, PhD, Victoria Coutinho, MSc, PhD, Thomas Goss, PharmD, Zhihong Lai, PhD, Sotiris Rompas, Phd, Michael F. Murphy, MD, PhD

Stakeholder Perspective

Challenges Surrounding the New Biosimilars Landscape

by Michael Kleinrock

Business

Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus

Machaon M. K. Bonafede, PhD, MPH, Arthi Chandran, MS, MPH, Laurence J Hirsch, MD, Betsy J Lahue, MPH, Sonali Nigam, MPH, Rita Saltiel-Berzin, RN, MPH, CDE, CHES

Stakeholder Perspective

Adherence to Antihyperglycemic Treatment Regimen Also Reduces Overall Costs

by Quang T. Nguyen, DO, FACE, FTOS

Conference Highlights AMCP

Payers’ Perspectives: Health Economics Outcomes in Managed Care

Charles Bankhead, Medical Writer

Results 1 - 5 of 5

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.